Comprehensive evaluation of immune dysregulation in secondary hemophagocytic lymphohistiocytosis

References

• Janka GE, Lehmberg K. Hemophagocytic syndromes–an update. Blood Rev. 2014;28(4):135–12. doi: 10.1016/j.blre.2014.03.002
   PubMed Web of Science ®Google Scholar
• Ishii E, Ohga S, Imashuku S, et al. Review of hemophagocytic lymphohistiocytosis (HLH) in children with focus on Japanese experiences. Crit Rev Oncol Hematol. 2005;53(3):209–223. doi: 10.1016/j.critrevonc.2004.11.002
   PubMed Web of Science ®Google Scholar
• Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr. 2007;166(2):95–109. doi: 10.1007/s00431-006-0258-1
   PubMed Web of Science ®Google Scholar
• La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465–2477. doi: 10.1182/blood.2018894618
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, López-Guillermo A, et al. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503–1516. doi: 10.1016/S0140-6736(13)61048-X
   PubMed Web of Science ®Google Scholar
• Chandrakasan S, Filipovich AH. Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment. J Pediatr. 2013;163(5):1253–1259. doi: 10.1016/j.jpeds.2013.06.053
   PubMed Web of Science ®Google Scholar
• Gholam C, Grigoriadou S, Gilmour KC, et al. Familial haemophagocytic lymphohistiocytosis: advances in the genetic basis, diagnosis and management. Clin Exp Immunol. 2011;163(3):271–283. doi: 10.1111/j.1365-2249.2010.04302.x
   PubMed Web of Science ®Google Scholar
• Henter JI, Horne A, Aricó M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–131. doi: 10.1002/pbc.21039
   PubMed Web of Science ®Google Scholar
• Madkaikar M, Shabrish S, Desai M. Current updates on classification, diagnosis and treatment of hemophagocytic lymphohistiocytosis (HLH). Indian J Pediatr. 2016;83(5):434–443. doi: 10.1007/s12098-016-2037-y
   PubMed Web of Science ®Google Scholar
• Put K, Avau A, Brisse E, et al. Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ. Rheumatology (Oxford). 2015;54(8):1507–1517. doi: 10.1093/rheumatology/keu524
   PubMed Web of Science ®Google Scholar
• Weitzman S. Approach to hemophagocytic syndromes.Hematology Am Soc Hematol Educ Program. 2011;2011(1):178–183. doi: 10.1182/asheducation-2011.1.178
   PubMedGoogle Scholar
• Bseiso O, Zahdeh A, Isayed O, et al. The role of immune mechanisms, inflammatory pathways, and macrophage activation syndrome in the pathogenesis of hemophagocytic lymphohistiocytosis. Cureus. 2022;14(12):e33175. doi: 10.7759/cureus.33175
   PubMed Web of Science ®Google Scholar
• McCall CM, Mudali S, Arceci RJ, et al. Flow cytometric findings in hemophagocytic lymphohistiocytosis. Am J Clin Pathol. 2012;137(5):786–794. doi: 10.1309/AJCPP40MEXWYRLPN
   PubMed Web of Science ®Google Scholar
• Noguchi M, Kawano Y, Sato N, et al. T-cell lymphoma of CD3+CD4+CD56+granular lymphocytes with hemophagocytic syndrome. Leuk Lymphoma. 1997;26(3–4):349–358. doi: 10.3109/10428199709051785
   PubMed Web of Science ®Google Scholar
• Wong KF, Chan JKC, Ma SK, et al. Aggressive pleomorphic CD2+, CD3-, CD56+ lymphoma with t(5;9)(q31;q34). Abnormality Cancer Genet Cytogenet. 1995;82(1):73–75. doi: 10.1016/0165-4608(94)00269-H
   PubMedGoogle Scholar
• Kelkar MG, Bargir UA, Malik-Yadav R, et al. CD8 + T cells exhibit an exhausted phenotype in hemophagocytic lymphohistiocytosis. J Clin Immunol. 2021;41(8):1794–1803. doi: 10.1007/s10875-021-01109-0
   PubMed Web of Science ®Google Scholar
• Nguyen TH, Kumar D, Prince C, et al. Frequency of HLA-DR(+)CD38(hi) T cells identifies and quantifies T-cell activation in hemophagocytic lymphohistiocytosis, hyperinflammation, and immune regulatory disorders. J Allergy Clin Immunol. 2023;153(1):309–319. doi: 10.1016/j.jaci.2023.07.008
   PubMed Web of Science ®Google Scholar
• Gao Z, Wang Y, Wang J, et al. The inhibitory receptors on NK cells and CTLs are upregulated in adult and adolescent patients with secondary hemophagocytic lymphohistiocytosis. Clin Immunol. 2019;202:18–28. doi: 10.1016/j.clim.2019.03.006
   PubMed Web of Science ®Google Scholar
• Zoref-Lorenz A, Murakami J, Hofstetter L, et al. An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis. Blood. 2022;139(7):1098–1110. doi: 10.1182/blood.2021012764
   PubMed Web of Science ®Google Scholar
• Otrock ZK, Eby CS. Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol. 2015;90(3):220–224. doi: 10.1002/ajh.23911
   PubMed Web of Science ®Google Scholar
• Cheng W, Wang L, Gao X, et al. Prognostic value of lipid profile in adult hemophagocytic lymphohistiocytosis. Front Oncol. 2023;13:1083088. doi: 10.3389/fonc.2023.1083088
   PubMed Web of Science ®Google Scholar
• Cheng W, Gao X, Yin G, et al. Characteristics and prognostic value of pleural effusion in secondary hemophagocytic lymphohistiocytosis. Int J Hematol. 2022;116(1):102–109. doi: 10.1007/s12185-022-03333-9
   PubMed Web of Science ®Google Scholar
• Dalal BI, Vakil AP, Khare NS, et al. Abnormalities of the lymphocyte subsets and their immunophenotype, and their prognostic significance in adult patients with hemophagocytic lymphohistiocytosis. Ann Hematol. 2015;94(7):1111–1117. doi: 10.1007/s00277-015-2350-y
   PubMed Web of Science ®Google Scholar
• Henter JI, Elinder G, Söder O, et al. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatric Scand. 1991;80(4):428–435. doi: 10.1111/j.1651-2227.1991.tb11878.x
   PubMed Web of Science ®Google Scholar
• Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med. 2012;63(1):233–246. doi: 10.1146/annurev-med-041610-134208
   PubMedGoogle Scholar
• Ravelli A, Davì S, Minoia F, et al. Macrophage Activation Syndrome. Hematol Oncol Clin North Am. 2015;29(5):927–941. doi: 10.1016/j.hoc.2015.06.010
   PubMed Web of Science ®Google Scholar
• Parikh SA, Kapoor P, Letendre L, et al. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc. 2014;89(4):484–492. doi: 10.1016/j.mayocp.2013.12.012
   PubMed Web of Science ®Google Scholar
• Imashuku S, Morimoto A, Ishii E. Virus-triggered secondary hemophagocytic lymphohistiocytosis. Acta Paediatr. 2021;110(10):2729–2736. doi: 10.1111/apa.15973
   PubMed Web of Science ®Google Scholar
• Setiadi A, Zoref-Lorenz A, Lee CY, et al. Malignancy-associated haemophagocytic lymphohistiocytosis. Lancet Haematol. 2022;9(3):e217–e227. doi: 10.1016/S2352-3026(21)00366-5
   PubMed Web of Science ®Google Scholar
• Chaturvedi V, Marsh RA, Zoref-Lorenz A, et al. T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis. Blood. 2021;137(17):2337–2346. doi: 10.1182/blood.2020009499
   PubMed Web of Science ®Google Scholar
• De Matteis A, Colucci M, Rossi MN, et al. Expansion of CD4dimCD8+ T cells characterizes macrophage activation syndrome and other secondary HLH. Blood. 2022;140(3):262–273. doi: 10.1182/blood.2021013549
   PubMed Web of Science ®Google Scholar
• Tang G, Yuan X, Luo Y, et al. Establishing immune scoring model based on combination of the number, function, and phenotype of lymphocytes. aging Albany NY. Aging. 2020;12(10):9328–9343. doi: 10.18632/aging.103208
   PubMedGoogle Scholar
• Shim J, Park S, Venkateswaran S, et al. Early B-cell development and B-cell maturation are impaired in patients with active hemophagocytic lymphohistiocytosis. Blood. 2023;142(23):1972–1984. doi: 10.1182/blood.2023020426
   PubMed Web of Science ®Google Scholar
• Song P, Zheng N, Liu Y, et al. Deficient humoral responses and disrupted B-cell immunity are associated with fatal SFTSV infection. Nat Commun. 2018;9(1):3328. doi: 10.1038/s41467-018-05746-9
   PubMed Web of Science ®Google Scholar
• Beckers L, Somers V, Fraussen J. IgD(-)CD27(-) double negative (DN) B cells: Origins and functions in health and disease. Immunol Lett. 2023;255:67–76. doi: 10.1016/j.imlet.2023.03.003
   PubMed Web of Science ®Google Scholar
• Li Y, Li Z, Hu F. Double-negative (DN) B cells: an under-recognized effector memory B cell subset in autoimmunity. Clin Exp Immunol. 2021;205(2):119–127. doi: 10.1111/cei.13615
   PubMed Web of Science ®Google Scholar
• Rohr J, Beutel K, Maul-Pavicic A, et al. Atypical familial hemophagocytic lymphohistiocytosis due to mutations in UNC13D and STXBP2 overlaps with primary immunodeficiency diseases. Haematologica. 2010;95(12):2080–2087. doi: 10.3324/haematol.2010.029389
   PubMed Web of Science ®Google Scholar
• Voskoboinik I, Dunstone MA, Baran K, et al. Perforin: structure, function, and role in human immunopathology. Immunol Rev. 2010;235(1):35–54. doi: 10.1111/j.0105-2896.2010.00896.x
   PubMedGoogle Scholar
• Law RH, Lukoyanova N, Voskoboinik I, et al. The structural basis for membrane binding and pore formation by lymphocyte perforin. Nature. 2010;468(7322):447–451. doi: 10.1038/nature09518
   PubMed Web of Science ®Google Scholar
• Mellor-Heineke S, Villanueva J, Jordan MB, et al. Elevated granzyme b in cytotoxic lymphocytes is a signature of immune activation in hemophagocytic lymphohistiocytosis. Front Immunol. 2013;4:72. doi: 10.3389/fimmu.2013.00072
   PubMed Web of Science ®Google Scholar
• Wang J, Wang Y, Wu L, et al. Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis. Haematologica. 2020;105(5):e210–e212. doi: 10.3324/haematol.2019.222471
   PubMed Web of Science ®Google Scholar
• Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020;382(19):1811–1822. doi: 10.1056/NEJMoa1911326
   PubMed Web of Science ®Google Scholar
• Fajgenbaum DC, June CH, Longo DL. Cytokine Storm. N Engl J Med. 2020;383(23):2255–2273. doi: 10.1056/NEJMra2026131
   PubMed Web of Science ®Google Scholar
• Betjes MG, Meijers RWJ, de Wit LEA, et al. A killer on the road: circulating CD4(+)CD28null T cells as cardiovascular risk factor in ESRD patients. J Nephrol. 2012;25(2):183–191. doi: 10.5301/jn.5000057
   PubMed Web of Science ®Google Scholar
• Ugarte-Gil MF, Sánchez-Zúñiga C, Gamboa-Cardenas RV, et al. Peripheral CD4+CD28null T-cells as predictors of damage in systemic lupus erythematosus patients. Clin Exp Rheumatol. 2018;36(6):1008–1013.
   PubMed Web of Science ®Google Scholar
• Xiong J, Li Z, Tang H, et al. Bulk and single-cell characterisation of the immune heterogeneity of atherosclerosis identifies novel targets for immunotherapy. BMC Biol. 2023;21(1):46. doi: 10.1186/s12915-023-01540-2
   PubMed Web of Science ®Google Scholar
• Jordan MB, Hildeman D, Kappler J, et al. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood. 2004;104(3):735–743. doi: 10.1182/blood-2003-10-3413
   PubMed Web of Science ®Google Scholar
• Yoon JH, Park S-S, Jeon Y-W, et al. Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancy. Haematologica. 2019;104(2):269–276. doi: 10.3324/haematol.2018.198655
   PubMed Web of Science ®Google Scholar